INTRODUCTION
Resectable non-small-cell lung cancer (NSCLC) accounts for 20% to 25% of lung cancer cases diagnosed annually; however, only 60% of patients survive 5 years after surgery. 1 The first trial to demonstrate a significant survival benefit with adjuvant cisplatin-based chemotherapy was reported a decade ago. 2 Subsequently, additional randomized trials confirmed the role of adjuvant chemotherapy in patients with pathologic stage II and III NSCLC, and subset analyses suggested a benefit in patients with large IB tumors. 3-5 A meta-analysis provided further support for adjuvant chemotherapy. 1 Although a cisplatin-based regimen is the treatment of choice, its significant toxicity may limit its use.
Erlotinib, an oral, small-molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR), has proven efficacy in the treatment of advanced stage NSCLC in three distinct settings: in an unselected and previously treated patient population (BR.21) 6 ; as maintenance therapy in nonprogressing patients who had received a platinum doublet (Sequential Tarceva in Unresectable NSCLC; SATURN) 7 ; and as first-line therapy in patients whose tumors have EGFR exon 19 deletion/exon 21 L858R-activating mutations (European Randomized Trial of Tarceva v Chemotherapy; EURTAC). 8 Efforts have been made to identify patients most likely to respond to EGFR-TKIs. An exploratory analysis of the BR.21 study revealed that patients whose tumor expressed EGFR protein by immunohistochemistry (IHC), high polysomy, or amplification of EGFR by fluorescence in situ hybridization (FISH) had prolonged survival with erlotinib treatment. 9 Similarly, patients with EGFR IHC-positive or EGFR FISH-positive tumors had superior survival with gefitinib compared with placebo. 10 Collectively, these results suggested, at the time of protocol design, that EGFR expression by IHC or EGFR gene copy number may predict EGFR-TKI benefit. This hypothesis was not supported by a subsequent maintenance trial in the metastatic setting. 11 The signal of activity observed with erlotinib in patients with EGFR-expressing tumors combined with its oral availability and mild nonhematologic toxicity profile led to its evaluation in earlier stages of lung cancer. The Randomized Double-Blind Trial in Adjuvant NSCLC With Tarceva (RADIANT) study evaluated whether erlotinib would increase disease-free survival (DFS) in patients with completely resected stage IB to IIIA NSCLC whose tumors express EGFR.
PATIENTS AND METHODS

Study Design and Patients
RADIANT was a randomized, double-blind, placebo-controlled phase III trial conducted in 204 centers across 19 countries. Adult patients with completely resected, early-stage NSCLC were eligible if they had pathologically confirmed stage IB to IIIA (microscopic N2 only) disease by the American Joint Committee on Cancer 6th edition staging system. 12 Primary tumor tissue must have been analyzed by the central laboratory and determined to be EGFR-positive by IHC (Ն 1% staining) and/or FISH (EGFR amplification [EGFR gene-to-chromosome ratio of Ն 2 or Ն 15 EGFR gene copies in Ն 10% of tumor cells] or high polysomy [Ն 4 EGFR gene copies in Ն 40% of tumor cells]). EGFR and KRAS mutation status was also determined by the central laboratory using WAVE HS (Transgenomic, Omaha, NE) and confirmed by Sanger sequencing. Patients must have started treatment within 3 months from surgery or if they received adjuvant chemotherapy within 6 months from surgery. Patients had to have an Eastern Oncology Cooperative Group performance status of 0 to 2 and adequate organ function. Neoadjuvant systemic therapy or adjuvant radiotherapy was not allowed. All patients provided written informed consent. Institutional review boards/ethics committees approved the protocol at all participating institutions. The study was conducted in accordance with the protocol, International Conference on Harmonization guidelines, including Good Clinical Practice, and the ethical principles that have their origin in the Declaration of Helsinki. An independent data and safety monitoring committee reviewed safety and efficacy data.
Random Assignment and Masking
Patients were randomly assigned in a 2:1 ratio to receive oral erlotinib (150 mg) or placebo once per day for 2 years. Patients were stratified according to stage, histology, previous adjuvant chemotherapy, smoking status, EGFR FISH status, and country. An adaptive random assignment method by Pocock and Simon 13 was used with a minimization probability parameter of 0.80. For patients receiving adjuvant chemotherapy, random assignment occurred at least 21 days from day 1 of last cycle. Baseline radiologic assessments were to be performed after surgery and within 42 days before random assignment.
Study Assessment
Patients underwent a baseline history and physical examination, postoperative computed tomography (CT) of the chest and upper abdomen, a chest radiograph, complete blood cell count, and metabolic panel. During the treatment period, CT scans were repeated at months 6, 12, 18, and 24 and chest radiographs at months 3, 9, 15, and 21. Laboratory and toxicity assessments were performed at months 1 and 3 and every 3 months thereafter during the treatment period. During the long-term follow-up period, CT scans were performed yearly and patients were observed every 6 months until year 5 and yearly thereafter. Adverse event (AE) grading was conducted according to the Common Terminology Criteria for Adverse Events, version 3.0. 14 Two dose reductions were allowed. Patients were discontinued from study treatment for unacceptable toxicity, patient or physician request, or disease relapse.
Outcomes
The primary end point was DFS in the intent-to-treat (ITT) population, defined as the time from random assignment to relapse or until death in the absence of relapse. Key secondary end points included overall survival (OS) in the ITT population, DFS, OS in the EGFR-activating mutations (EGFRmpositive) subgroup, and safety.
Statistical Analysis
The study was designed to have 80% power to detect a 33% improvement in median DFS (hazard ratio [HR], 0.75) with erlotinib (two-sided log-rank test with 5% significance) for all randomly assigned patients. The final DFS analysis would occur at 410 DFS events. The sample size calculation was based on a two-look group sequential design. One interim analysis for efficacy was planned when 75% (308 events) of the required 410 DFS events occurred. A Lan-DeMets ␣ spending function with an O'Brien-Fleming boundary was used at the interim analysis to maintain an overall ␣ of .05.
The null hypothesis was that DFS of the two arms was equivalent. The alternative hypothesis was that DFS was longer in either arm. The interim analysis occurred at 304 DFS events with an ␣ of .0185; the primary DFS analysis was performed at 410 events with an ␣ of .0445. If the primary DFS analysis was statistically significant favoring erlotinib, the null hypothesis for key secondary efficacy variables would be tested hierarchically in the following order: OS in the ITT population, DFS, and then OS in the EGFRm-positive subgroup.
RESULTS
The study was activated in 2006. A total of 2,500 patients were screened; 2,395 patients had results for both EGFR IHC and FISH. Among these patients, 92.1%, 67.9%, and 64.6% were positive for EGFR by IHC, FISH, or both, respectively; only 3.3% were negative for EGFR by both IHC and FISH. Approximately 50% of patients proceeded to random assignment. After 278 patients were randomly assigned, a drug-labeling error was discovered and enrollment was restarted. Data from the breached patient cohort are not included herein. From November 2007 through July 2010, 973 patients were randomly assigned (Fig 1; data on one additional patient were removed from the database because of inadequate Health Insurance Portability and Accountability Act documentation), with 623 and 350 patients in the erlotinib and placebo arms, respectively. A total of 11 patients (1.8%) assigned to erlotinib and 8 patients (2.3%) assigned to placebo did not receive treatment. The study groups were well balanced with respect to demographics and clinical characteristics ( Table  1 ). Most patients were white, male, younger than 65 years, had a smoking history, and had stage IB adenocarcinoma. More than one half of the patients received adjuvant chemotherapy. The EGFRmpositive subgroup accounted for 16.5% (n ϭ 161) of the total patient population. Of those patients, 55.3% (n ϭ 89) and 44.7% (n ϭ 72) had del19 and L858R mutations, respectively. In contrast to the ITT population, these patients were more likely to be female, never smokers, and Asian (Table 1) .
At the April 2013 cutoff, there were 410 (42%) DFS events and 277 (15%) deaths. The median follow-up time was 47 months. There was no significant between-arm difference in DFS (HR, 0.90; 95% CI, 0.741 to 1.104; P ϭ .324; Fig 2A) . The median DFS was 50.5 months for erlotinib and 48.2 months for placebo. For subgroup analyses, refer to Table 2 . The OS data are immature, with death occurring in 28% of patients (Appendix Table A1 , online only). No survival difference in OS was observed (HR, 1.13; 95% CI, 0.881 to 1.448; P ϭ .335; Appendix Fig A1A, online only). The stratified DFS analyses yielded consistent results.
In the EGFRm-positive subgroup, 102 patients were randomly assigned to erlotinib and 59 patients to placebo. Some imbalances were observed, with more patients in the erlotinib arm having stage IB and more patients in the placebo arm having stage IIIA disease. A smaller proportion of patients receiving erlotinib had lobectomies and received adjuvant chemotherapy (Table 1) . Prolonged DFS was not seen in the EGFRm-positive subgroup for patients treated with erlotinib (HR, 0.61; 95% CI, 0.384 to 0.981; Fig 2B) . The median DFS was 46.4 and 28.5 months, with 2-year DFS rates of 75% and 54% for erlotinib and placebo, respectively. This result was not statistically significant because of hierarchical testing. The median DFS in the placebo arm in the EGFRm-positive subgroup was shorter than that in the ITT population (28.5 and 48.2 months, respectively). In a post hoc exploratory analysis of EGFRm-positive patients, correcting for other variables (stage, previous chemotherapy, age, sex, smoking status, EGFR mutation type, and tumor size), the treatment effect on DFS (HR, 0.60; 95% CI, 0.362 to 0.978; P ϭ .041) was consistent with the unadjusted analysis. Analysis by EGFR mutation type showed similar results between del19 and L858R subgroups (HR, 0.68 [95% CI, 0.36 to 1.28] and HR, 0.55 [95% CI, 0.27 to 1.12], respectively). The OS data are immature, with 35 deaths (22%) reported (Appendix Table  A1 ). There was no between-arm difference in OS (HR, 1.09; 95% CI, 0.545 to 2.161; P ϭ .815; Appendix Fig A1B, online only).
KRAS testing was performed on 828 patient samples. Seventeen percent (n ϭ 143; 96 and 47 in the erlotinib and placebo groups, respectively) of the samples had a mutation. KRAS mutations were found in 120 (21%) of 578 patients with adenocarcinoma. KRAS mutational status was not prognostic nor was it predictive of a benefit to erlotinib. 14 The most common site of relapse was lung in the ITT population and EGFRmϩ subgroup (Appendix Table A2 , online only). Among the 66 patients with EGFRmϩ tumors who experienced a relapse, a higher rate of brain relapse was reported with erlotinib (n ϭ 13; 37.1%) versus placebo (n ϭ 4; 1.9%), and a lower rate of bone relapse with erlotinib (n ϭ 5; 14.3%) versus placebo (n ϭ 9; 29.0%).
The safety analysis was conducted on 954 (98%) of patients who received treatment. An AE was reported in 98.0% of patients receiving erlotinib and 89.5% of patients receiving placebo. Rash (defined as a CONSORT diagram. (*) One additional patient was randomly assigned and received study drug but did not have appropriate Health Insurance Portability and Accountability Act documentation at the site; consequently, data for this patient were removed from the database per institutional review board request. grouped term) was the most common AE, occurring in 86.4% and 32.1% of patients, respectively (Table 3) . Diarrhea was more frequent with erlotinib (52.2% versus 15.7% for placebo). Grade 3 or greater AEs that occurred in the erlotinib arm with a 1% or greater absolute difference between arms were rash (22.3%), diarrhea (6.2%), and pruritus (1.3%). Drug-related serious AEs occurred in 2.5% of patients receiving erlotinib and 1.5% of patients receiving placebo. Deaths on treatment or within 30 days of last dose of study drug occurred in 2.0% of patients receiving erlotinib and 0.9% of patients receiving placebo (Appendix Table A1 ). No treatment-related deaths occurred. AEs leading to permanent discontinuation occurred in 33.6% of patients receiving erlotinib and 8.5% of patients receiving placebo. An AE led to dose reduction, temporary interruption, or both in 24.5%, 18.5%, and 25.5% of patients receiving erlotinib and in 2.6%, 6.7%, and 1.5% of patients receiving placebo.
The median treatment duration in the ITT population was 11.9 and 21.9 months for erlotinib and placebo, respectively. Dose reductions occurred in 44.4% of patients receiving erlotinib versus 3.8% of patients receiving placebo. Completion of planned treatment was reported as the reason for discontinuing treatment in 40.6% and 56.3% of randomly assigned patients in the erlotinib and placebo arms, respectively (41.3% and 57.6% of treated patients in the erlotinib and placebo arms, respectively).
The safety profile for the 159 treated patients in the EGFRmpositive subgroup was similar to the overall population (Table 3) . Rash and diarrhea were more frequent for erlotinib, at 93.0% and 62.0%, respectively, versus 40.7% and 18.6% for placebo, respectively. Grade 3 or greater AEs occurring in more than 2% of patients were experienced in patients receiving erlotinib only (rash, 19%; and diarrhea, 5%). An AE leading to permanent discontinuation occurred in 30.0% of patients receiving erlotinib and in 5.1% of patients receiving placebo. AEs led to dose reduction, interruption, or both in 22.0%, 22.0%, and 34.0% of patients receiving erlotinib versus 1.7%, 6.8%, and 1.7% of patients receiving placebo.
The median treatment duration in the EGFRm-positive subgroup was 21.2 and 21.9 months for erlotinib and placebo, respec-tively. Dose reductions occurred in 46.0% of patients receiving erlotinib versus 3.4% of patients receiving placebo. Most erlotinib dose reductions were 100 mg. Completion of planned treatment was reported as the reason treatment was discontinued in 52.9% of erlotinib-treated patients and 54.2% of placebo-treated patients.
DISCUSSION
Adjuvant erlotinib did not improve DFS in patients with EGFR IHCor FISH-positive tumor in this trial. Our hypothesis that this subset of patients might benefit from adjuvant erlotinib was based on data from retrospective exploratory biomarker analyses of two trials in advanced NSCLC (BR.21 15 and ISEL [Iressa Survival Evaluation in Lung Cancer] 10 ), which suggested that IHC and FISH might be predictive of EGFR-TKI efficacy. Subsequent to activation of RADIANT, results from two phase III studies failed to show that EGFR expression by IHC or FISH was predictive of EGFR-TKI responsiveness in the metastatic setting. The INTEREST (Iressa NSCLC Trial Evaluating Response and Survival Versus Taxotere) trial, a noninferiority trial of gefitinib versus docetaxel in previously treated patients, did not meet its coprimary end point for EGFR FISH positivity to predict improved survival with gefitinib. 16 EGFR protein expression also was not shown to predict improved survival with gefitinib. 16 The SATURN trial, which evaluated erlotinib or placebo as maintenance therapy after a first-line doublet in unselected patients, met its coprimary end point of prolonging progression-free survival in patients with 10% or greater EGFR IHC expression; however, the prospective molecular marker analysis did not demonstrate that EGFR expression by IHC or FISH was predictive of erlotinib responsiveness. 11 During the years, emerging data have demonstrated that EGFRm-positive del19 and L858R are the strongest predictors of EGFR-TKI sensitivity in advanced disease. Our study, the largest prospective data set of resected EGFRm-positive NSCLC treated with an EGFR-TKI, is limited because patients were not stratified by EGFR mutation status. Stratification by EGFRm-positive status was not feasible, because a substantial proportion of patients were already enrolled by the time definitive evidence emerged in the literature. There were between-arm imbalances in some disease characteristics, and the placebo arm in the EGFRm-positive subgroup had substantially worse DFS than the ITT population. Thus, interpretation of the near doubling of the median DFS with erlotinib in the EGFRmpositive subgroup is limited. A possible benefit for adjuvant EGFR-TKI was suggested in a retrospective analysis of 167 patients with resected stage I to IIIA NSCLC with EGFR-mutated tumors. 17 Fifty-six patients (33%) received an EGFR-TKI. In a multivariable analysis, the 2-year DFS rate was 89% for the EGFR-TKI group versus 72% for the untreated group (HR, 0.53; 95% CI, 0.28 to 1.03; P ϭ .06). These data led to a singlearm, multi-institutional, prospective phase II study known as the SELECT trial, in which 100 patients with resected stage IA to IIIA NSCLC and an EGFR-mutated tumor received adjuvant erlotinib for 2 years after standard-of-care treatment. 18 With a median follow-up of 3.4 years, the 2-year DFS rate was encouraging at 89%. 18 These results must be viewed cautiously and cannot be compared directly with our results because of the differences in patient characteristics, especially the inclusion of patients with stage IA disease, the shorter follow-up time, and the lack of an untreated control arm.
We undertook an exploratory analysis to determine if KRAS mutation status could have influenced our results. We did not observe a prognostic or predictive role for KRAS mutational status, but our analysis is limited by small patient numbers.
No new safety signals were observed in the overall population or in the EGFRm-positive subgroup. Although a slight imbalance of deaths was observed during the treatment period, there were no treatment-related deaths. Erlotinib treatment duration was substantially longer in the EGFRm-positive subgroup than in the overall group, despite a similar rate of AEs, perhaps because patients with clinical characteristics associated with an increased frequency of having an EGFRm-positive tumor were encouraged to remain on treatment (results of centralized EGFR mutation testing were not provided to investigators unless requested, which rarely occurred). Slightly more than half of the patients in the mutant subgroup completed the planned treatment period.
It is not known if a longer treatment duration would have provided a different result. Two years of therapy was selected to be consistent with the BR.19 study and the SWOG 0023 trial, which evaluated postoperative adjuvant and maintenance gefitinib in patients with locally advanced lung cancer, respectively. 19, 20 Data supporting evaluation of a longer duration of adjuvant EGFR-TKI come from the SELECT trial, in which only four patients experienced relapse while still receiving erlotinib. 18 A treatment duration longer than that studied in this trial may be needed to achieve the goal of increasing the cure rate of early-stage NSCLC in an EGFRm-positive population. We observed that early-stage patients are often unwilling to tolerate even modest toxicity, and so a starting dose of lower than 150 mg once per day may be needed for future adjuvant studies to minimize toxicity and improve compliance. The efficacy of a lower dose of erlotinib has not been studied prospectively in a randomized trial in patients with NSCLC. There have been reports of responses in patients with EGFRm-positive advanced NSCLC receiving 25 mg once per day 21 ; however, a single-arm phase II study 22 and a retrospective series 23 suggest that response rate and progression-free survival observed with a reduced erlotinib dose may not be equivalent to that of the standard dose. In conclusion, this study did not show a DFS benefit for erlotinib in patients with IHC-or FISH-positive NSCLC. Similarly, the study failed to demonstrate a DFS benefit for erlotinib in the EGFRmpositive subgroup. The trend toward improvement in DFS with erlotinib in the EGFRm-positive subgroup warrants further evaluation. A phase III US intergroup trial of adjuvant erlotinib in EGFRm-positive NSCLC is actively enrolling patients.
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